Contrast-induced acute kidney injury: How should at-risk patients be identified and managed?

Journal of Nephrology

Volumn 23, Issue 4, 2010, Pages 387-398

  Laville, Maurice ^a   Juillard, Laurent ^a  

^a UNIVERSITÉ DE LYON   (France)

Author keywords

Computed tomography; Contrast induced acute kidney injury; Contrast induced nephropathy (CIN); Coronary angiography; Iodinated contrast agent; Percutaneous coronary intervention

Indexed keywords

ACETYLCYSTEINE; BICARBONATE; CONTRAST MEDIUM; CREATININE; CYSTATIN C; IODINATED CONTRAST MEDIUM; IODIXANOL; IOHEXOL; IOMEPROL; IOPAMIDOL; IOPROMIDE; IOVERSOL; IOXAGLIC ACID; MEGLUMINE IOXAGLATE PLUS SODIUM IOXAGLATE; PLASMA SUBSTITUTE; SODIUM CHLORIDE;

AGING; ANGIOCARDIOGRAPHY; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTRAST INDUCED NEPHROPATHY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DRUG INDICATION; DRUG MEGADOSE; GLOMERULUS FILTRATION RATE; HIGH RISK PATIENT; HUMAN; KIDNEY DYSFUNCTION; LOW DRUG DOSE; MORBIDITY; MORTALITY; NEPHROTOXICITY; OSMOLARITY; PRACTICE GUIDELINE; QUESTIONNAIRE; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SCORING SYSTEM; SCREENING TEST; ACUTE DISEASE; CHEMICALLY INDUCED; CLINICAL TRIAL (TOPIC); KIDNEY DISEASE;

ACUTE DISEASE; CLINICAL TRIALS AS TOPIC; CONTRAST MEDIA; HUMANS; KIDNEY DISEASES; RISK FACTORS;

EID: 77955505948     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Mehta RL, Kellum JA, Shah SV, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11:R31.
2. Thomsen HS. ESUR guidelines on contrast media, version 7.0. Heidelberg, Germany: European Society of Urogenital Radiology; 2008.
3. Nikolsky E, Aymong ED, Dangas G, Mehran R. Radiocontrast nephropathy: identifying the high-risk patient and the implications of exacerbating renal function. Rev Cardiovasc Med. 2003;4(Suppl 1):S7-S14. (Pubitemid 36124205)
4. Goldfarb S, McCullough PA, McDermott J, Gay SB. Contrast-induced acute kidney injury: specialty-specific protocols for interventional radiology, diagnostic computed tomography radiology, and interventional cardiology. Mayo Clin Proc. 2009;84:170-179.
5. Dangas G, Iakovou I, Nikolsky E, et al. Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. Am J Cardiol. 2005;95:13-19.
6. Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation. 2002;105:2259-2264.
7. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med. 1997;103:368-375. (Pubitemid 27506242)
8. Harjai K, Shenoy C, Raizada A, et al. Major adverse noncardiac events after PCI as predictors of long-term mortality. J Interv Cardiol. 2008;21:395-402.
9. Moscucci M, Rogers EK, Montoye C, et al. Association of a continuous quality improvement initiative with practice and outcome variations of contemporary percutaneous coronary interventions. Circulation. 2006;113:814-822.
10. From AM, Bartholmai BJ, Williams AW, Cha SS, McDonald FS. Mortality associated with nephropathy after radiographic contrast exposure. Mayo Clin Proc. 2008;83:1095-1100.
11. Reddan D, Fishman EK. Radiologists' knowledge and perceptions of the impact of contrast-induced nephropathy and its risk factors when performing computed tomography examinations: a survey of European radiologists. Eur J Radiol. 2007;66:235-245. (Pubitemid 351626392)
12. Elicker BM, Cypel YS, Weinreb JC. IV contrast administration for CT: a survey of practices for the screening and prevention of contrast nephropathy. AJR Am J Roentgenol. 2006;186:1651-1658.
13. Weisbord SD, Bruns FJ, Saul MI, Palevsky PM. Provider use of preventive strategies for radiocontrast nephropathy in high-risk patients. Nephron Clin Pract. 2004;96:c56-c62.
14. Radiology. ACo. Manual on contrast media, version 6. Available at: http://www.acr.org/SecondaryMainMenuCategories/quality-safety/contrast-manual. aspx. Accessed April 9, 2008.
15. Cigarroa RG, Lange RA, Williams RH, Hillis LD. Dosing of contrast material to prevent contrast nephropathy in patients with renal disease. Am J Med. 1989;86:649-652.
16. Laskey WK, Jenkins C, Selzer F, et al. Volume-to-creatinine clearance ratio. J Am Coll Cardiol. 2007;50:584-590.
17. Marenzi G, Assanelli E, Campodonico J, et al. Contrast volume during primary percutaneous coronary intervention and subsequent contrast-induced nephropathy and mortality. Ann Intern Med. 2009;150:170-177.
18. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons. Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol. 2007;50:652-726.
19. King SB III, Smith SC Jr, Hirshfeld JW Jr, et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation. 2008;117:261-295.
20. Choyke PL, Cady J, DePollar SL, Austin H. Determination of serum creatinine prior to iodinated contrast media: is it necessary in all patients? Tech Urol. 1998;4:65-69.
21. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
22. Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139:137-147.
23. Detrenis S, Meschi M, Bertolini L, Savazzi G. Contrast medium administration in the elderly patient: is advancing age an independent risk factor for contrast nephropathy after angiographic procedures? J Vasc Interv Radiol. 2007;18:177-185.
24. Toprak O. Conflicting and new risk factors for contrast-induced nephropathy. J Urol. 2007;178:2277-2283. (Pubitemid 350052198)
25. World Health Organization. The world is growing fast: have we noticed? 2007. Available at: http://www.who.int/topics/ageing/en/index.html.
26. International Diabetes Federation. Diabetes facts and figures. 2006. Available at: http://www.idf.org/home/index.cfm?node=6.
27. Lameire N, Jager K, Van Biesen W, de Bacquer D, Vanholder R. Chronic kidney disease: a European perspective. Kidney Int Suppl. 2005;99:S30-S38.
28. Manske CL, Sprafka JM, Strony JT, Wang Y. Contrast nephropathy in azotemic diabetic patients undergoing coronary angiography. Am J Med. 1990;89:615-620.
29. Sidhu RB, Brown JR, Robb JF, et al. Interaction of gender and age on post cardiac catheterization contrast-induced acute kidney injury. Am J Cardiol. 2008;102:1482-1486.
30. El-Hajjar M, Bashir I, Khan M, Min J, Torosoff M, DeLago A. Incidence of contrast-induced nephropathy in patients with chronic renal insufficiency undergoing multidetector computed tomographic angiography treated with preventive measures. Am J Cardiol. 2008;102:353-356.
31. Weisbord SD, Mor MK, Resnick AL, Hartwig KC, Palevsky PM, Fine MJ. Incidence and outcomes of contrast-induced AKI following computed tomography. Clin J Am Soc Nephrol. 2008;3:1274-1281.
32. McCullough PA, Stacul F, Davidson C, et al. Overview. Am J Cardiol. 2006;98:2-4.
33. Cirillo M, Anastasio P, De Santo NG. Relationship of gender, age, and body mass index to errors in predicted kidney function. Nephrol Dial Transplant. 2005;20:1791-1798.
34. Band RA, Gaieski DF, Mills AM, et al. Discordance between serum creatinine and creatinine clearance for identification of ED patients with abdominal pain at risk for contrast-induced nephropathy. Am J Emerg Med. 2007;25:268-272.
35. Herts BR, Schneider E, Poggio ED, Obuchowski NA, Baker ME. Identifying outpatients with renal insufficiency before contrast-enhanced CT by using estimated glomerular filtration rates versus serum creatinine levels. Radiology. 2008;248:106-113.
36. Pucci L, Triscornia S, Lucchesi D, et al. Cystatin C and estimates of renal function: searching for a better measure of kidney function in diabetic patients. Clin Chem. 2007;53:480-488.
37. Royakkers AA, van Suijlen JD, Hofstra LS, et al. Serum cystatin C: a useful endogenous marker of renal function in intensive care unit patients at risk for or with acute renal failure? Curr Med Chem. 2007;14:2314-2317.
38. Kato K, Sato N, Yamamoto T, Iwasaki YK, Tanaka K, Mizuno K. Valuable markers for contrast-induced nephropathy in patients undergoing cardiac catheterization. Circ J. 2008;72:1499-1505.
39. Coca SG, Yalavarthy R, Concato J, Parikh CR. Biomarkers for the diagnosis and risk stratification of acute kidney injury: a systematic review. Kidney Int. 2008;73:1008-1016. (Pubitemid 351543898)
40. Bennett MR, Ravipati N, Ross G, et al. Using proteomics to identify preprocedural risk factors for contrast induced nephropathy. Proteomics Clin Appl. 2008;2:1058-1064.
41. Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004;44:1393-1399. (Pubitemid 39303939)
42. Bartholomew BA, Harjai KJ, Dukkipati S, et al. Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. Am J Cardiol. 2004;93:1515-1519.
43. Skelding KA, Best PJ, Bartholomew BA, Lennon RJ, O'Neill WW, Rihal CS. Validation of a predictive risk score for radiocontrast-induced nephropathy following percutaneous coronary intervention. J Invasive Cardiol. 2007;19:229-233.
44. Brown JR, DeVries JT, Piper WD, et al. Serious renal dysfunction after percutaneous coronary interventions can be predicted. Am Heart J. 2008;155:260-266.
45. Briguori C, Airoldi F, D'Andrea D, et al. Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): A randomized comparison of 3 preventive strategies. Circulation. 2007;115:1211-1217. (Pubitemid 46594764)
46. Ozcan EE, Guneri S, Akdeniz B, et al. Sodium bicarbonate, N-acetylcysteine, and saline for prevention of radiocontrast-induced nephropathy: a comparison of 3 regimens for protecting contrast-induced nephropathy in patients undergoing coronary procedures: a single-center prospective controlled trial. Am Heart J. 2007;154:539-544.
47. Reddan D, Laville M, Garovic VD. Contrast-induced nephropathy (CIN) and its prevention: what do we really know from evidence-based findings? J Nephrol. 2009;22:333-351.
48. Tippins RB, Torres WE, Baumgartner BR, Baumgarten DA. Are screening serum creatinine levels necessary prior to outpatient CT examinations? Radiology. 2000;216:481-484.
49. Pannu N, Wiebe N, Tonelli M. Prophylaxis strategies for contrast-induced nephropathy. JAMA. 2006;295:2765-2779.
50. McCullough PA. Multimodality prevention of contrast-induced acute kidney injury. Am J Kidney Dis. 2008;51:169-172.
51. Hogan SE, L'Allier P, Chetcuti S, et al. Current role of sodium bicarbonate-based preprocedural hydration for the prevention of contrast-induced acute kidney injury: a meta-analysis. Am Heart J. 2008;156:414-421.
52. Bader BD, Berger ED, Heede MB, et al. What is the best hydration regimen to prevent contrast media-induced nephrotoxicity? Clin Nephrol. 2004;62:1-7.
53. Trivedi HS, Moore H, Nasr S, et al. A randomized prospective trial to assess the role of saline hydration on the development of contrast nephrotoxicity. Nephron Clin Pract. 2003;93:C29-C34.
54. Dussol B, Morange S, Loundoun A, Auquier P, Berland Y. A randomized trial of saline hydration to prevent contrast nephropathy in chronic renal failure patients. Nephrol Dial Transplant. 2006;21:2120-2126.
55. Kane GC, Doyle BJ, Lerman A, Barsness GW, Best PJ, Rihal CS. Ultra-low contrast volumes reduce rates of contrast-induced nephropathy in patients with chronic kidney disease undergoing coronary angiography. J Am Coll Cardiol. 2008;51:89-90.
56. Nyman U, Björk J, Aspelin P, Marenzi G. Contrast medium dose-to-GFR ratio: a measure of systemic exposure to predict contrast-induced nephropathy after percutaneous coronary intervention. Acta Radiol. 2008;49:658-667.
57. Nyman U, Almen T, Aspelin P, Hellstrom M, Kristiansson M, Sterner G. Contrast-medium-induced nephropathy correlated to the ratio between dose in gram iodine and estimated GFR in mL/min. Acta Radiol. 2005;46:830-842.
58. Rao QA, Newhouse JH. Risk of nephropathy after intravenous administration of contrast material: a critical literature analysis. Radiology. 2006;239:392-397.
59. Newhouse JH, Kho D, Rao QA, Starren J. Frequency of serum creatinine changes in the absence of iodinated contrast material: implications for studies of contrast nephrotoxicity. AJR Am J Roentgenol. 2008;191:376-382.
60. Bruce RJ, Djamali A, Shinki K, Michel SJ, Fine JP, Pozniak MA. Background fluctuation of kidney function versus contrast-induced nephrotoxicity. AJR Am J Roentgenol. 2009;192:711-718.
61. Hardiek KJ, Katholi RE, Robbs RS, Katholi CE. Renal effects of contrast media in diabetic patients undergoing diagnostic or interventional coronary angiography. J Diabetes Complications. 2008;22:171-177. (Pubitemid 351552047)
62. Feldkamp T, Baumgart D, Elsner M, et al. Nephrotoxicity of iso-osmolar versus low-osmolar contrast media is equal in low risk patients. Clin Nephrol. 2006;66:322-330.
63. Jo SH, Youn TJ, Koo BK, et al. Renal toxicity evaluation and comparison between Visipaque (iodixanol) and Hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study: a randomized controlled trial. J Am Coll Cardiol. 2006;48:924-930.
64. Aspelin P, Aubry P, Fransson SG, Strasser R, Willenbrock R, Berg KJ. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med. 2003;348:491-499.
65. Nie B, Cheng WJ, Li YF, et al. A prospective, double-blind, randomized, controlled trial on the efficacy and cardiorenal safety of iodixanol vs. iopromide in patients with chronic kidney disease undergoing coronary angiography with or without percutaneous coronary intervention. Catheter Cardiovasc Interv. 2008;72:958-965.
66. Solomon RJ, Natarajan MK, Doucet S, et al. Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease. Circulation. 2007;115:3189-3196.
67. Rudnick MR, Davidson C, Laskey W, Stafford JL, Sherwin PF. Nephrotoxicity of iodixanol versus ioversol in patients with chronic kidney disease: the Visipaque Angiography/Interventions with Laboratory Outcomes in Renal Insufficiency (VALOR) Trial. Am Heart J. 2008;156:776-782.
68. Kuhn MJ, Chen N, Sahani DV, et al. The PREDICT study: a randomized double-blind comparison of contrast-induced nephropathy after low- or isoosmolar contrast agent exposure. AJR Am J Roentgenol. 2008;191:151-157.
69. Thomsen HS, Morcos SK, Erley CM, Grazioloi L, Bonomo L, Ni Z. The ACTIVE Trial: comparison of the effects on renal function of iomeprol-400 and idoixanol-320 in patients with chronic kidney disease undergoing abdominal computed tomography. Invest Radiol. 2008;43:170-178.
70. Barrett BJ, Katzberg RW, Thomsen HS, et al. Contrast-induced nephropathy in patients with chronic kidney disease undergoing computed tomography: a double-blind comparison of iodixanol and iopamidol. Invest Radiol. 2006;41:815-821.
71. Nguyen SA, Suranyi P, Ravenel JG, et al. Iso-osmolality versus low-osmolality iodinated contrast medium at intravenous contrast-enhanced CT: effect on kidney function. Radiology. 2008;248:97-105.
72. Solomon RJ, Mehran R, Natarajan M, et al. Contrast-induced nephropathy and long-term adverse events: cause and effect? Clin J Am Soc Nephrol. 2009;4:1162-1169.
73. National Kidney Foundation. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Available at: http://www.kidney. org/professionals/KDOQI/guidelines-cvd/guide2.htm. Accessed January 2008, 2005.
74. Aguiar-Souto P, Valero-Gonzalez S. When to test renal function to disclose contrast-induced nephropathy. Am J Cardiol. 2008;102:371.